Nectar Lifesciences (NSE:NECLIFE) Construction In Progress: ₹0 Mil (As of Mar. 2026)


NSE:NECLIFE Nectar Lifesciences Ltd NSE:NECLIFE
51 GF Score
Price ₹11.22
GF Value ₹6.86
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Nectar Lifesciences Construction In Progress?

Nectar Lifesciences NSE:NECLIFE -2.26% 51 Construction In Progress is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:NECLIFE with a GF Score™ of 51/100 and a GF Value™ of ₹6.86 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Nectar Lifesciences's annual construction in progress declined from Mar. 2024 (₹658 Mil) to Mar. 2025 (₹567 Mil) and declined from Mar. 2025 (₹567 Mil) to Mar. 2026 (₹0 Mil).

Nectar Lifesciences Construction In Progress Historical Data

* Premium members only.

The historical data trend for Nectar Lifesciences's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nectar Lifesciences Construction In Progress Chart

Nectar Lifesciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 850.98 777.83 657.50 567.28 0.00

Nectar Lifesciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 567.28 0.00 0.00 0.00 0.00
NSE:NECLIFE
51GF Score
Nectar Lifesciences Ltd NSE:NECLIFE
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nectar Lifesciences Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of ₹0 Mil mean?
Nectar Lifesciences (NSE:NECLIFE) has a Construction In Progress of ₹0 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Nectar Lifesciences and its competitors.
Is Nectar Lifesciences' Construction In Progress too high?
Nectar Lifesciences' current Construction In Progress is ₹0 Mil. Overall, Nectar Lifesciences has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nectar Lifesciences' Construction In Progress compare to ZTS and UTHR?
Nectar Lifesciences' Construction In Progress of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Nectar Lifesciences and its competitors. Nectar Lifesciences's current Construction In Progress is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nectar Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Nectar Lifesciences (NSE:NECLIFE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹6.86, compared to a current price of ₹11.22 — trading 63.6% above its estimated fair value. The current Construction In Progress is ₹0 Mil. Nectar Lifesciences' overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Nectar Lifesciences (NSE:NECLIFE), the current Construction In Progress is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nectar Lifesciences (NSE:NECLIFE) Overvalued in 2026?

Based on GuruFocus' analysis, Nectar Lifesciences stock appears to be overvalued. The current stock price of ₹11.22 is trading 63.6% above its estimated GF Value™ of ₹6.86. GuruFocus considers Nectar Lifesciences to be Significantly Overvalued.

Key valuation signals for NSE:NECLIFE:

  • Construction In Progress: ₹0 Mil
  • GF Value™: ₹6.86 vs. price of ₹11.22 (63.6% above fair value)
  • GF Score™: 51/100 with 2 warning signs

No single metric tells the full story. See the NSE:NECLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nectar Lifesciences Business Description

Other Exchanges 532649:India
Address S.C.O. 38-39, Sector 9-D, B-1011/1012, 10th Floor NAURANG HOUSE, Chandigarh, IND, 160009
Nectar Lifesciences Ltd is an India-based pharmaceutical company specializing in Cephalosporins. It is engaged in manufacturing specialized pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage formulations. It operates in the business segment of Pharmaceuticals Products. The Company is also in the Menthol business and succeeded in both domestic and international markets. Its business areas are APIs, Formulations, and Empty Hard Gelatin Capsules. Geographically, it derives a majority of its revenue from India.
51GF Score

Get the complete analysis for NSE:NECLIFE

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹11.22
Price
₹6.86
GF Value